logo
These 4 Habits Could Help You Avoid Cognitive Decline, New Study Says

These 4 Habits Could Help You Avoid Cognitive Decline, New Study Says

Yahoo3 days ago
Reviewed by Dietitian Mandy Enright, M.S., RDN, RYTKey Points
A new study suggests exercise, diet and regular healthcare check-ups may lower dementia risk.
That includes physical exercise—ideally six times per week—and mental exercises to keep you sharp.
Following the MIND diet, a combination of the Mediterranean and DASH diets, may also support better brain health.Alzheimer's disease (AD) and related dementias are significant public health challenges for many reasons. More people are being affected by dementia, and the condition can bring heavy emotional, social and financial burdens. And as much as you or a loved one may want to lower your dementia risk, it can be hard to figure out where to start.
Memory decline in older adults often has multiple causes, so effective treatments ideally tackle several targets at once. While new medications that target amyloid (a group of proteins linked to Alzheimer's) show promise in slowing the disease in its early stages, they don't address other common problems like blood vessel damage in the brain, which can also contribute to memory loss. This highlights the need for better, more comprehensive treatments.
Non-drug approaches, like improving lifestyle factors, offer a safe, affordable, and accessible way to reduce dementia risk. A groundbreaking study in Finland (called the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, or FINGER) showed that combining certain healthy lifestyle changes improved memory and thinking in older adults at risk for dementia.
To determine if the positive results from the FINGER study in Finland could also apply to a larger and more diverse group of people in the United States who are at risk for dementia, researchers studied this method's impact on brain health and thinking abilities, and the results were published in JAMA. This study was called the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk, or U.S. POINTER.
How Was This Study Conducted?
Researchers recruited subjects for this study by using electronic health records and by working with local community organizations to reach people directly. The goal was to include older adults (ages 60 to 79) who didn't have memory problems but were at higher risk of developing dementia.
To qualify, participants had to meet specific criteria regarding both lifestyle factors and risk factors. Those factors included having low physical activity levels—meaning less than 60 minutes of moderate exercise per week—and not following the MIND diet, which is designed to support brain health. As for risk factors, participants needed to meet at least two of the following conditions:
A close family member (like a parent or sibling) had memory problems.
They had health risks like high blood pressure, high cholesterol or high blood sugar.
They identified as part of a racial or ethnic group that is often underrepresented in research, such as Native American, Black, Middle Eastern, or Hispanic or Latino.
They were in the older age range (70 to 79 years old) or were male, as men are often underrepresented in dementia prevention studies.
Both groups focused on improving brain health through physical activity, cognitive activity, healthy eating, social engagement and heart health monitoring. The difference between the two groups was in how the program was delivered. The first group was the structured group, and participants in this group received extra support from trained professionals and worked closely with peer teams of 10-15 people for motivation and accountability. Participants attended 38 team meetings over two years, and meetings were led by trained navigators and specialists. They also participated in the following:
Physical exercise: 30-35 minutes of moderate-to-intense aerobic activity four times a week, plus strength and flexibility exercises twice a week.
Cognitive exercise: Computer-based brain training program three times a week for 30 minutes, plus regular engagement in other intellectually challenging and social activities.
Nutrition: Adherence to the MIND diet, which emphasizes dark leafy greens, berries, nuts, whole grains, olive oil and fish, and limits sugar and unhealthy fats.
Health monitoring: Regular check-ins (every 6 months) on blood pressure, weight and lab results.
The second group was the self-guided group. This group was more independent but still had access to resources and support from peer teams and navigators from the Alzheimer's Association. Participants received publicly available resources about healthy lifestyle changes, such as tips on exercise, diet and brain health. They only attended six peer team meetings over two years, and had their health checked once a year during clinic visits, following standard health guidelines.
This study measured brain health and thinking abilities using a global cognitive score, which combined results from three key areas: executive function, which includes skills like planning, problem-solving, and multitasking; episodic memory, which focuses on remembering specific events or experiences; and processing speed, which measures how quickly the brain can handle information. To calculate the global score, participants completed a series of brain tests during clinic visits at the start of the study and every six months for two years.
What Did The Study Find?
Both groups in the U.S. POINTER study showed improvements in overall brain function over time as measured by their global cognitive scores. After adjusting for certain factors, the structured group improved slightly faster than the self-guided group, and this difference was statistically significant.
When focusing on the different cognitive areas the researchers measured, here is what they found:
Executive Function: In planning, problem-solving and multitasking, the structured group improved more than the self-guided group, and the difference was statistically significant.
Processing Speed: In gauging how long the brain took to process information, the structured group also showed slightly greater improvement—however, this difference was not statistically significant.
Episodic Memory: As for remembering specific events, both groups improved at about the same rate, with no meaningful difference between them.
The structured program seemed to have the biggest impact on participants who started the study with lower cognitive function. However, the structured program worked similarly well regardless of participants' sex, age or heart health at the start of the study. Additionally, the effects of the structured program were the same for people with or without the APOE ε4 gene, which research has linked to a higher risk of Alzheimer's disease.
In summary, the structured program provided the most benefit for executive function and was especially helpful for participants who started with lower cognitive abilities. Other factors like age, sex and genetic risk didn't seem to change how effective the program was.
This study has a few limitations to consider. First, the results might not apply to everyone because the study only took place at five sites, included participants specifically at higher risk for cognitive decline and required a significant two-year commitment from participants. Second, the study wasn't designed to measure whether the interventions could prevent cognitive impairment or dementia, so those outcomes remain unknown.
It's also worth noting that the self-guided group wasn't a true 'no-intervention' control group, as they still received some resources and support. Plus, participants knew which group they were in, which could have influenced their behavior or results. Additionally, it's unclear how long the benefits of the structured program will last, how easily it could be scaled up for larger populations or how meaningful the improvements are in the long term.
How Does This Apply to Real Life?
This study highlights the power of lifestyle changes when it comes to supporting brain health and reducing the risk of memory decline. It shows that combining regular exercise, a brain-healthy diet, mental stimulation and social engagement may make a real difference, especially for people at higher risk of dementia.
The structured program, which provided extra guidance and support, was particularly effective in improving skills like planning, problem-solving and multitasking. This observation suggests that having a clear plan and access to professional support may help people stick to healthy habits and see better results. But the self-guided group, which had more flexibility, showed improvements, proving that small, consistent changes in daily life can still benefit brain health.
This means that adopting healthier habits like staying active, following the MIND diet, engaging in mentally challenging activities, and staying socially connected can be a practical and accessible way to protect brain health. While the study focused on older adults at risk for dementia, the findings are a reminder that it's never too early or too late to start making positive changes.
Our Expert Take
A study recently published in JAMA provides valuable evidence that lifestyle changes can play a significant role in supporting brain health and reducing the risk of cognitive decline. In particular, these findings highlight the potential of combining regular exercise, a brain-healthy diet, mental stimulation and social engagement to improve cognitive health, especially for those at higher risk of dementia.
Both structured and self-guided programs led to improvements in overall brain function, with the structured program showing slightly greater benefits, particularly in areas like planning, problem-solving, and multitasking. Importantly, the study also demonstrated that even small, self-guided changes can make a meaningful difference, making these strategies accessible to a wide range of people.
Read the original article on EATINGWELL
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference

Yahoo

time11 minutes ago

  • Yahoo

New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference

STOCKHOLM, SE / / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract about the preclinical project TrkA-NAM ACD137 against osteoarthritis and other severe pain conditions has been accepted for presentation at the international pain conference NeuPSIG 2025, to be held in Berlin, Germany, September 4-6. The abstract, titled Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA , will be presented at NeuPSIG 2025 by Märta Segerdal, Head of Development and Chief Medical Officer at AlzeCure Pharma. Co-authors are Pontus Forsell, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Gunnar Nordvall. The results show that the lead drug candidate in the project, ACD137, has potent analgesic effects in several different preclinical pain models. The analgesic effect of ACD137 in the study was as potent as the effect of the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several clinical trials. ACD137 achieves its effect by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain. These positive preclinical data in models of osteoarthritis, neuropathic pain and nociceptive pain further strengthen previous positive analgesic results obtained with ACD137 and further underline its broad applicability in various severe pain conditions, including osteoarthritis. "These data demonstrate that our drug candidate ACD137 is a highly potent and selective TrkA-NAM that exhibits significant analgesic effects in relevant preclinical animal models. Furthermore, this small molecule TrkA-NAM has the potential to avoid some of the side effects observed with anti-NGF antibodies due to a more selective mechanism of action, while maintaining analgesic efficacy," said Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure Pharma. "The project is based on a mechanism with strong validation, both preclinically and clinically. The results we have for TrkA-NAM in pain are promising, and the fact that we also have anti-inflammatory effects with our substance opens up for broader application. The fact that this is also a mechanism that is not linked to the side effects and addiction problems observed with opioids and antibodies is of course also important for a potential future approval," said Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and the poster will be available on AlzeCure's website after the presentation ( For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit About TrkA-NAMThe TrkA-NAM project, which is in research phase, is focused on the treatment of pain. The target mechanism, NGF / TrkA signaling, is well-validated both preclinically and clinically and provides a promising alternative to new analgesics without the side effects and addiction problems observed with opioids. Substances developed in the project have recently been shown to also have anti-inflammatory properties. For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain. The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator for the treatment of osteoarthritis pain and other severe pain disorders. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 400 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field. Read more about TrkA-NAM on our homepage. Image Attachments Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma Attachments New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

Yahoo

time43 minutes ago

  • Yahoo

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland, August 05, 2025--(BUSINESS WIRE)--Polpharma Biologics S.A. ("Polpharma Biologics") announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. "This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally," said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. "Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases." The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy. View source version on Contacts Media contacts Natalia Kwiecień

Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements
Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements

Yahoo

time43 minutes ago

  • Yahoo

Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements

The cystinosis market is poised for growth amid increasing newborn screening, innovative cysteamine formulations, and potential gene therapy breakthroughs. As a rare metabolic disorder, cystinosis is marked by cystine accumulation, primarily affecting kidneys and eyes. While cysteamine remains a cornerstone treatment, its long-term use presents challenges. Advances in gene therapy trials, renal transplantation, and metabolic screening are enhancing patient management. North America leads the market, followed by Europe, with Asia-Pacific showing rising potential. Key players like Recordati Rare Diseases and Amgen drive the competitive landscape, offering new opportunities in this focused healthcare segment. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cystinosis Market - A Global and Regional Analysis: Focus on Type, Drug Class, and Region - Analysis and Forecast, 2025-2035" report has been added to development of delayed release cysteamine formulations, ongoing gene therapy trials, and improvements in renal transplantation techniques are reshaping disease management. Technological advancements in metabolic screening and growing collaboration among stakeholders are enabling more effective and accessible treatment advancements, challenges persist such as treatment adherence, side effects of long-term cysteamine use, and limited availability of specialized care in low-income regions. Nonetheless, the growing focus on rare disease awareness, expansion of clinical trials, and regulatory support for orphan drugs are expected to sustain market America is expected to dominate the cystinosis market owing to advanced healthcare systems, robust rare disease registries, and presence of key market players. Europe follows closely, driven by strong orphan drug policies and centralized healthcare systems. Asia-Pacific shows emerging growth potential due to increasing rare disease awareness and investment in genetic diagnostics. Key Market Players and Competition Synopsis The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global cystinosis market. How can this report add value to an organization?Product/Innovation: This report provides comprehensive insights into the current trends in cystinosis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from cystinosis, improving outcomes and enhancing market A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global cystinosis Drivers and Limitations Demand Drivers for the Global Cystinosis Market: Increasing newborn screening and early diagnosis rates Continued innovation in cysteamine formulations and delivery systems Emergence of gene therapy as a potentially curative treatment Regulatory incentives and support for orphan drugs Limitations for the Global Cystinosis Market: High cost and side effects of lifelong pharmacological treatment Limited access to expert care and specialized facilities in developing regions Treatment adherence challenges among pediatric patients Leading players in the global cystinosis market include: Recordati Rare Diseases Amgen Inc Viatris Inc Leadiant Biosciences, Inc Novartis AG Nacuity Pharmaceuticals, Inc CHIESI Farmaceutici S.p.A. Papillon Therapeutics Inc Key Topics Covered: 1. Global Cystinosis Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cystinosis Market, by Type, $Million, 2023-20352.1 Nephropathic Cystinosis2.2 Intermediate Cystinosis2.3 Non-Nephropathic Cystinosis3. Global Cystinosis Market, by Drug Class, $Million, 2023-20353.1 Cysteamine Bitartrate (Immediate-Release)3.2 Cysteamine Bitartrate (Delayed-Release)3.3 Others4. Global Cystinosis Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cystinosis Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cystinosis Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cystinosis Market, by Country4.3.3.1 Japan5. Global Cystinosis Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store